Dana C Beausang, MD
Endocrinology · Dublin
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
- Since medical school
- 21 years
- University of Missouri, Columbia School of Medicine, 2005
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beausang’s office at (925) 875-6100 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A116528 · Current
Licensed to practise in California · since 2011 · expires 2028-10-31 · Columbia University College of Physicians and Surgeons.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Endocrinology, Diabetes and Metabolism
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$185,509
Medicare paid this office $185,509 for 401 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 271 | $50,011 | $107 |
| Long return visit (40+ min) | 72 | $13,819 | $147 |
| New patient visit (45+ min) | 77 | $11,451 | $149 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 260 | $5,328 | $14 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 64 | $4,462 | $29 |
See all 10 services
| Return visit (30+ min) | 271 | $50,011 | $107 |
| Long return visit (40+ min) | 72 | $13,819 | $147 |
| New patient visit (45+ min) | 77 | $11,451 | $149 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 260 | $5,328 | $14 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 64 | $4,462 | $29 |
| New patient visit (60+ min) | 21 | $3,906 | $186 |
| Short return visit (20+ min) | 42 | $3,117 | $74 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 18 | $2,529 | $133 |
| Injection of drug or substance under skin or into muscle | 17 | $1,355 | $14 |
| Blood glucose (sugar) test performed by hand-held instrument | 11 | $39 | $3 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 18 | – | 14 | 12 | 13 | 19 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
401 Original Medicare patients in 2024. Average age 74 · Under 65 5% · 85 and older 10% · Women 70% · Also on Medicaid 10% · Health risk score 1.03. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 59% · Diabetes 42% · Chronic kidney disease 25% · Coronary heart disease 23% · Depression 15% · Cancer 14% · Atrial fibrillation 14% · Heart failure 8% · COPD 6% · Dementia 5% · Stroke 4%.
The office billed $635,290, Medicare allowed $245,873 and paid $185,509; for 10,949 services of 17 kinds; $87,616 of it was for drugs given in the office and $97,892 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 401 | 10,949 | 74 | 1.03 | $635,290 | $185,509 |
| 2023 | 323 | 9,785 | 74 | 1.09 | $444,275 | $136,617 |
| 2022 | 402 | 1,583 | 74 | 1.09 | $328,599 | $92,519 |
| 2021 | 428 | 10,350 | 74 | 1.13 | $540,271 | $174,522 |
| 2020 | 398 | 10,948 | 74 | 1.33 | $550,759 | $165,541 |
| 2019 | 459 | 9,838 | 73 | 1.37 | $528,346 | $146,815 |
| 2018 | 377 | 6,530 | 73 | 1.47 | $388,700 | $107,892 |
| 2017 | 331 | 3,222 | 72 | 1.48 | $338,768 | $91,596 |
| 2016 | 357 | 3,489 | 73 | 1.43 | $353,686 | $94,377 |
| 2015 | 260 | 1,795 | 73 | 1.31 | $267,965 | $77,220 |
| 2014 | 214 | 1,179 | 71 | 1.33 | $234,843 | $65,801 |
| 2013 | 97 | 450 | 71 | 1.33 | $94,960 | $27,810 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 200 | $35,600 | $110 |
| Long return visit (40+ min) | 66 | $12,526 | $146 |
| New patient visit (60+ min) | 46 | $9,510 | $207 |
| New patient visit (45+ min) | 62 | $8,893 | $143 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 43 | $2,893 | $30 |
| Short return visit (20+ min) | 28 | $1,934 | $69 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 12 | $1,760 | $135 |
| Injection of drug or substance under skin or into muscle | 12 | $1,240 | $14 |
2022: 9 services
| Return visit (30+ min) | 281 | $46,616 | $102 |
| Long return visit (40+ min) | 77 | $16,223 | $149 |
| New patient visit (45+ min) | 54 | $6,857 | $127 |
| New patient visit (60+ min) | 29 | $5,775 | $199 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 64 | $3,827 | $29 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 14 | $2,660 | $156 |
| Short return visit (20+ min) | 33 | $1,980 | $60 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 11 | $1,638 | $136 |
| Blood glucose (sugar) test performed by hand-held instrument | 17 | $65 | $3 |
2021: 11 services
| Return visit (30+ min) | 329 | $68,120 | $108 |
| Injection, denosumab, 1 mg | 45 | $62,934 | None |
| Long return visit (40+ min) | 74 | $16,566 | $151 |
| New patient visit (45+ min) | 39 | $5,668 | $145 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 68 | $4,942 | $30 |
| Short return visit (20+ min) | 37 | $3,175 | $76 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 16 | $3,156 | $166 |
| New patient visit (60+ min) | 14 | $2,571 | $184 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 14 | $1,899 | $136 |
| Injection of drug or substance under skin or into muscle | 50 | $1,574 | $13 |
| Blood glucose (sugar) test performed by hand-held instrument | 44 | $171 | $3 |
2020: 13 services
| Injection, denosumab, 1 mg | 45 | $68,096 | None |
| Return visit (30+ min) | 320 | $53,344 | $90 |
| Long return visit (40+ min) | 74 | $12,115 | $126 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 37 | $6,163 | $154 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 78 | $4,346 | $31 |
| New patient visit (45+ min) | 20 | $2,768 | $138 |
| Short return visit (20+ min) | 39 | $2,451 | $61 |
| New patient visit (60+ min) | 13 | $2,375 | $183 |
| Injection of drug or substance under skin or into muscle | 51 | $1,806 | $14 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,760 | $104 |
| Influenza vaccine split virus, preservative free | 18 | $1,098 | $61 |
| Administration of influenza virus vaccine | 18 | $371 | $21 |
| Blood glucose (sugar) test performed by hand-held instrument | 35 | $131 | $3 |
2019: 10 services
| Return visit (30+ min) | 322 | $53,835 | $90 |
| Injection, denosumab, 1 mg | 39 | $46,279 | None |
| Long return visit (40+ min) | 91 | $13,446 | $129 |
| New patient visit (45+ min) | 89 | $12,172 | $137 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 37 | $6,252 | $160 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 68 | $3,277 | $32 |
| Short return visit (20+ min) | 47 | $3,131 | $61 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 17 | $2,205 | $123 |
| Injection of drug or substance under skin or into muscle | 47 | $1,716 | $16 |
| Blood glucose (sugar) test performed by hand-held instrument | 49 | $180 | $3 |
2018: 12 services
| Return visit (30+ min) | 267 | $50,017 | $90 |
| Injection, denosumab, 1 mg | 14 | $20,143 | None |
| New patient visit (45+ min) | 78 | $11,040 | $142 |
| Long return visit (40+ min) | 50 | $7,356 | $123 |
| Short return visit (20+ min) | 51 | $3,236 | $59 |
| Fine needle aspiration using imaging guidance | 14 | $2,609 | $137 |
| New patient visit (60+ min) | 11 | $2,079 | $189 |
| Injection of drug or substance under skin or into muscle | 22 | $1,586 | $18 |
| Ultrasonic guidance for needle placement | 14 | $825 | $55 |
| Influenza vaccine split virus, preservative free | 17 | $743 | $44 |
| Administration of influenza virus vaccine | 19 | $481 | $25 |
| Blood glucose (sugar) test performed by hand-held instrument | 45 | $161 | $3 |
2017: 11 services
| Return visit (30+ min) | 260 | $46,584 | $87 |
| Injection, denosumab, 1 mg | 13 | $14,798 | None |
| Long return visit (40+ min) | 52 | $7,850 | $119 |
| New patient visit (45+ min) | 53 | $7,342 | $139 |
| Fine needle aspiration using imaging guidance | 20 | $3,896 | $134 |
| Short return visit (20+ min) | 48 | $3,292 | $60 |
| Ultrasonic guidance for needle placement | 19 | $1,185 | $56 |
| Injection of drug or substance under skin or into muscle | 18 | $870 | $24 |
| Influenza vaccine split virus, preservative free | 17 | $750 | $44 |
| Administration of influenza virus vaccine | 21 | $653 | $31 |
| Blood glucose (sugar) test performed by hand-held instrument | 26 | $91 | $3 |
2016: 12 services
| Return visit (30+ min) | 232 | $41,337 | $87 |
| Injection, denosumab, 1 mg | 16 | $15,249 | None |
| New patient visit (45+ min) | 82 | $11,180 | $136 |
| Long return visit (40+ min) | 77 | $11,167 | $127 |
| Fine needle aspiration using imaging guidance | 25 | $4,345 | $132 |
| Short return visit (20+ min) | 57 | $4,033 | $63 |
| New patient visit (60+ min) | 16 | $2,613 | $163 |
| Ultrasonic guidance for needle placement | 25 | $1,402 | $56 |
| Influenza vaccine split virus, preservative free | 23 | $850 | $37 |
| Administration of influenza virus vaccine | 26 | $778 | $30 |
| Injection of drug or substance under skin or into muscle | 15 | $670 | $24 |
| Blood glucose (sugar) test performed by hand-held instrument | 46 | $172 | $3 |
2015: 9 services
| Return visit (30+ min) | 177 | $36,514 | $92 |
| New patient visit (45+ min) | 93 | $13,634 | $147 |
| Long return visit (40+ min) | 44 | $7,227 | $131 |
| Fine needle aspiration using imaging guidance | 12 | $2,313 | $136 |
| New patient visit (60+ min) | 11 | $2,071 | $188 |
| Short return visit (20+ min) | 29 | $1,833 | $59 |
| Ultrasonic guidance for needle placement | 11 | $610 | $51 |
| Injection of drug or substance under skin or into muscle | 11 | $553 | $25 |
| Blood glucose (sugar) test performed by hand-held instrument | 44 | $175 | $3 |
2014: 5 services
| Return visit (30+ min) | 127 | $27,569 | $90 |
| New patient visit (45+ min) | 115 | $14,956 | $130 |
| Long return visit (40+ min) | 32 | $4,821 | $127 |
| Short return visit (20+ min) | 34 | $2,586 | $62 |
| Blood glucose (sugar) measurement using reagent strip | 59 | $296 | $4 |
2013: 5 services
| New patient visit (45+ min) | 53 | $7,668 | $145 |
| Return visit (30+ min) | 50 | $5,904 | $95 |
| New patient visit (60+ min) | 16 | $2,856 | $178 |
| Long return visit (40+ min) | 19 | $2,787 | $127 |
| Short return visit (20+ min) | 23 | $1,889 | $65 |
Drugs they prescribed that Part D paid
$1,173,606
Pharmacies billed $1,173,606 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,575) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,294 generic and 1,138 brand-name prescriptions · $1,173,606 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 166 | $274,280 | $1,652 |
| Mounjaro | 135 | $218,169 | $1,616 |
| Jardiance | 136 | $199,338 | $1,466 |
| Trulicity | 80 | $150,188 | $1,877 |
| Tresiba Flextouch U-100 | 57 | $34,986 | $614 |
See all 40 drugs
| Ozempic | 166 | $274,280 | $1,652 |
| Mounjaro | 135 | $218,169 | $1,616 |
| Jardiance | 136 | $199,338 | $1,466 |
| Trulicity | 80 | $150,188 | $1,877 |
| Tresiba Flextouch U-100 | 57 | $34,986 | $614 |
| Rybelsus | 20 | $30,807 | $1,540 |
| Farxiga | 31 | $25,357 | $818 |
| Januvia | 15 | $20,238 | $1,349 |
| Tradjenta | 16 | $19,439 | $1,215 |
| Toujeo Solostar | 17 | $10,480 | $616 |
| Nano 2nd Gen Pen Needle | 87 | $9,989 | $115 |
| Humalog Kwikpen U-100 | 30 | $8,267 | $276 |
| Novolog Flexpen | 32 | $7,920 | $247 |
| Synthroid | 66 | $6,146 | $93 |
| Lantus Solostar | 48 | $5,545 | $116 |
| Levoxyl | 80 | $3,806 | $48 |
| Alendronate | 134 | $2,224 | $17 |
| Ultra-Fine Mini Pen Needle | 17 | $2,074 | $122 |
| Rosuvastatin | 85 | $2,052 | $24 |
| Metformin Hcl Er | 142 | $1,927 | $14 |
| Ultra-Fine Nano Pen Needle | 21 | $1,836 | $87 |
| Testosterone | 13 | $1,802 | $139 |
| Metformin | 192 | $1,763 | $9 |
| Levothyroxine | 155 | $1,712 | $11 |
| Eplerenone | 15 | $1,710 | $114 |
| Atorvastatin | 95 | $1,230 | $13 |
| Risedronate | 18 | $1,141 | $63 |
| Repaglinide | 43 | $1,120 | $26 |
| Losartan | 58 | $885 | $15 |
| Glipizide | 29 | $592 | $20 |
| Glipizide Er | 40 | $529 | $13 |
| Gabapentin | 15 | $434 | $29 |
| Lisinopril | 41 | $402 | $10 |
| Amlodipine Besylate | 30 | $382 | $13 |
| Ezetimibe | 15 | $299 | $20 |
| Calcitriol | 20 | $271 | $14 |
| Methimazole | 39 | $267 | $7 |
| Pioglitazone | 22 | $166 | $8 |
| Hydrochlorothiazide | 26 | $155 | $6 |
| Dexamethasone | 21 | $28 | $1 |
Year by year
| 2024 | 2,575 | 333 | 0% (0) | 44% | $1,173,606 |
| 2023 | 2,653 | 356 | 0% (0) | 45% | $1,438,356 |
| 2022 | 3,403 | 378 | 0% (0) | 44% | $1,866,452 |
| 2021 | 3,659 | 366 | 0% (0) | 45% | $1,893,910 |
| 2020 | 3,542 | 353 | 0% (0) | 47% | $1,622,019 |
| 2019 | 3,453 | 335 | 0% (0) | 47% | $1,483,777 |
| 2018 | 3,144 | 280 | None | 46% | $1,163,980 |
| 2017 | 2,809 | 259 | 0% (0) | 44% | $865,760 |
| 2016 | 2,399 | 243 | 0% (0) | 40% | $587,046 |
| 2015 | 1,714 | 175 | 0% (0) | 45% | $406,801 |
| 2014 | 1,257 | 168 | 0% (0) | 48% | $269,496 |
| 2013 | 1,406 | 155 | 0% (0) | 45% | $201,286 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 48 drugs
| Trulicity | 123 | $214,894 | $1,747 |
| Ozempic | 101 | $194,015 | $1,921 |
| Mounjaro | 96 | $180,995 | $1,885 |
| Jardiance | 119 | $172,404 | $1,449 |
| Novolog Flexpen | 48 | $53,062 | $1,105 |
| Tresiba Flextouch U-200 | 12 | $40,783 | $3,399 |
| Tradjenta | 31 | $38,405 | $1,239 |
| Januvia | 26 | $33,962 | $1,306 |
| Tresiba Flextouch U-100 | 50 | $33,955 | $679 |
| Lantus Solostar | 59 | $33,911 | $575 |
| Humalog Kwikpen U-100 | 23 | $32,948 | $1,433 |
| Farxiga | 31 | $32,154 | $1,037 |
| Novolog Mix 70-30 Flexpen | 18 | $26,201 | $1,456 |
| Rybelsus | 15 | $22,882 | $1,525 |
| Invokana | 13 | $22,719 | $1,748 |
| Toujeo Solostar | 23 | $12,806 | $557 |
| Levemir Flexpen | 14 | $11,545 | $825 |
| Nano 2nd Gen Pen Needle | 88 | $10,506 | $119 |
| Synthroid | 86 | $9,335 | $109 |
| Lantus | 13 | $8,162 | $628 |
| Basaglar Kwikpen U-100 | 19 | $6,967 | $367 |
| Eplerenone | 20 | $5,059 | $253 |
| Insulin Lispro Kwikpen U-100 | 13 | $3,268 | $251 |
| Levothyroxine | 173 | $2,962 | $17 |
| Ultra-Fine Nano Pen Needle | 24 | $2,901 | $121 |
| Rosuvastatin | 83 | $2,720 | $33 |
| Metformin | 194 | $2,604 | $13 |
| Metformin Hcl Er | 115 | $1,900 | $17 |
| Novolin 70-30 | 11 | $1,639 | $149 |
| Repaglinide | 20 | $1,635 | $82 |
| Levoxyl | 49 | $1,456 | $30 |
| Ultra-Fine Mini Pen Needle | 16 | $1,370 | $86 |
| Atorvastatin | 95 | $1,243 | $13 |
| Losartan | 59 | $1,153 | $20 |
| Glipizide | 60 | $1,126 | $19 |
| Alendronate | 89 | $1,094 | $12 |
| Glipizide Er | 41 | $1,089 | $27 |
| Methimazole | 53 | $734 | $14 |
| Gabapentin | 16 | $566 | $35 |
| Ezetimibe | 13 | $552 | $42 |
| Insulin | 15 | $552 | $37 |
| Pioglitazone | 28 | $450 | $16 |
| Lisinopril | 43 | $406 | $9 |
| Amlodipine Besylate | 39 | $341 | $9 |
| Calcitriol | 11 | $340 | $31 |
| Glimepiride | 23 | $328 | $14 |
| Hydrochlorothiazide | 36 | $181 | $5 |
| Dexamethasone | 28 | $20 | $1 |
2022: 60 drugs
| Trulicity | 244 | $447,055 | $1,832 |
| Jardiance | 164 | $248,692 | $1,516 |
| Ozempic | 55 | $120,192 | $2,185 |
| Novolog Flexpen | 73 | $86,541 | $1,185 |
| Tradjenta | 44 | $64,288 | $1,461 |
| Tresiba Flextouch U-100 | 73 | $52,103 | $714 |
| Humalog Kwikpen U-200 | 16 | $48,060 | $3,004 |
| Januvia | 29 | $45,962 | $1,585 |
| Mounjaro | 20 | $43,495 | $2,175 |
| Victoza 3-Pak | 20 | $43,125 | $2,156 |
| Lantus Solostar | 59 | $38,520 | $653 |
| Humalog Kwikpen U-100 | 22 | $36,274 | $1,649 |
| Tresiba Flextouch U-200 | 16 | $34,561 | $2,160 |
| Novolog Mix 70-30 Flexpen | 15 | $31,558 | $2,104 |
| Levemir Flextouch | 31 | $31,148 | $1,005 |
| Humalog | 21 | $29,248 | $1,393 |
| Toujeo Solostar | 33 | $26,757 | $811 |
| Invokana | 17 | $26,705 | $1,571 |
| Humalog Mix 75-25 Kwikpen | 12 | $26,029 | $2,169 |
| Fiasp Flextouch | 12 | $23,331 | $1,944 |
| Victoza 2-Pak | 25 | $18,996 | $760 |
| Lantus | 37 | $17,882 | $483 |
| Basaglar Kwikpen U-100 | 29 | $12,178 | $420 |
| Farxiga | 14 | $11,944 | $853 |
| Nano 2nd Gen Pen Needle | 89 | $10,926 | $123 |
| Novolog | 18 | $10,319 | $573 |
| Synthroid | 85 | $9,601 | $113 |
| Novolin 70-30 Flexpen | 19 | $9,277 | $488 |
| Novolog Penfill | 12 | $9,176 | $765 |
| Ultra-Fine Nano Pen Needle | 36 | $4,332 | $120 |
| Rosuvastatin | 117 | $4,327 | $37 |
| Testosterone | 14 | $4,045 | $289 |
| Insulin Lispro Kwikpen U-100 | 20 | $3,999 | $200 |
| Eplerenone | 14 | $3,986 | $285 |
| Repaglinide | 36 | $3,722 | $103 |
| Levothyroxine | 197 | $3,618 | $18 |
| Omega-3 Acid Ethyl Esters | 11 | $3,575 | $325 |
| Alendronate | 130 | $3,378 | $26 |
| Novolin 70-30 | 12 | $3,341 | $278 |
| Metformin Hcl Er | 184 | $2,971 | $16 |
| Metformin | 224 | $2,223 | $10 |
| Glipizide Er | 63 | $1,926 | $31 |
| Atorvastatin | 119 | $1,706 | $14 |
| Glipizide | 90 | $1,631 | $18 |
| Pioglitazone | 68 | $1,486 | $22 |
| Levoxyl | 41 | $1,398 | $34 |
| Ultra-Fine Mini Pen Needle | 19 | $1,363 | $72 |
| Hydrocortisone | 23 | $1,221 | $53 |
| Ulticare Pen Needle | 11 | $960 | $87 |
| Losartan | 54 | $916 | $17 |
| Gabapentin | 21 | $870 | $41 |
| Ezetimibe | 14 | $555 | $40 |
| Insulin | 15 | $510 | $34 |
| Glimepiride | 29 | $422 | $15 |
| Methimazole | 55 | $337 | $6 |
| Lisinopril | 50 | $319 | $6 |
| Amlodipine Besylate | 41 | $263 | $6 |
| Hydrochlorothiazide | 46 | $240 | $5 |
| Benazepril | 13 | $82 | $6 |
| Dexamethasone | 29 | $36 | $1 |
2021: 59 drugs
| Trulicity | 279 | $471,168 | $1,689 |
| Jardiance | 149 | $199,820 | $1,341 |
| Novolog Flexpen | 94 | $117,197 | $1,247 |
| Victoza 3-Pak | 50 | $102,941 | $2,059 |
| Ozempic | 38 | $71,628 | $1,885 |
| Humalog Kwikpen U-100 | 40 | $60,940 | $1,524 |
| Januvia | 42 | $55,365 | $1,318 |
| Tresiba Flextouch U-100 | 72 | $55,044 | $765 |
| Tradjenta | 40 | $52,850 | $1,321 |
| Novolog Mix 70-30 Flexpen | 24 | $51,133 | $2,131 |
| Lantus Solostar | 66 | $41,846 | $634 |
| Victoza 2-Pak | 44 | $32,916 | $748 |
| Levemir Flextouch | 34 | $32,617 | $959 |
| Toujeo Solostar | 37 | $31,596 | $854 |
| Tresiba Flextouch U-200 | 17 | $28,552 | $1,680 |
| Humalog Mix 75-25 Kwikpen | 11 | $26,970 | $2,452 |
| Lantus | 51 | $24,487 | $480 |
| Invokana | 23 | $21,837 | $949 |
| Testosterone | 26 | $20,585 | $792 |
| Janumet Xr | 12 | $18,222 | $1,518 |
| Humalog | 23 | $15,943 | $693 |
| Novolog | 22 | $15,775 | $717 |
| Synjardy Xr | 12 | $15,086 | $1,257 |
| Basaglar Kwikpen U-100 | 27 | $12,266 | $454 |
| Nano 2nd Gen Pen Needle | 129 | $11,406 | $88 |
| Novolin 70-30 Flexpen | 21 | $8,694 | $414 |
| Synthroid | 73 | $7,850 | $108 |
| Novolin 70-30 | 23 | $5,939 | $258 |
| Ultra-Fine Nano Pen Needle | 52 | $5,151 | $99 |
| Levothyroxine | 190 | $4,511 | $24 |
| Rosuvastatin | 97 | $3,475 | $36 |
| Levoxyl | 57 | $3,236 | $57 |
| Metformin Hcl Er | 150 | $2,543 | $17 |
| Repaglinide | 29 | $2,280 | $79 |
| Glipizide Er | 81 | $2,056 | $25 |
| Ultra-Fine Mini Pen Needle | 29 | $2,001 | $69 |
| Atorvastatin | 124 | $1,893 | $15 |
| Metformin | 216 | $1,862 | $9 |
| Pioglitazone | 83 | $1,644 | $20 |
| Nateglinide | 19 | $1,607 | $85 |
| Alendronate | 114 | $1,503 | $13 |
| Glipizide | 94 | $1,447 | $15 |
| Hydrocortisone | 34 | $1,300 | $38 |
| Ulticare Pen Needle | 21 | $1,113 | $53 |
| Novolin R | 11 | $1,045 | $95 |
| Losartan | 57 | $971 | $17 |
| Insulin | 21 | $860 | $41 |
| Veo Insulin | 16 | $694 | $43 |
| Methimazole | 64 | $606 | $9 |
| Testosterone Cypionate | 13 | $550 | $42 |
| Amlodipine Besylate | 51 | $463 | $9 |
| Gabapentin | 16 | $438 | $27 |
| Lisinopril | 59 | $350 | $6 |
| Glimepiride | 21 | $341 | $16 |
| Hydrochlorothiazide | 39 | $323 | $8 |
| Euthyrox | 21 | $292 | $14 |
| Lisinopril-Hydrochlorothiazide | 15 | $171 | $11 |
| Amlodipine Besylate-Benazepril | 15 | $82 | $5 |
| Dexamethasone | 29 | $30 | $1 |
2020: 58 drugs
| Trulicity | 304 | $439,773 | $1,447 |
| Victoza 3-Pak | 66 | $132,985 | $2,015 |
| Novolog Flexpen | 90 | $100,160 | $1,113 |
| Jardiance | 66 | $88,619 | $1,343 |
| Novolog Mix 70-30 Flexpen | 39 | $58,080 | $1,489 |
| Tresiba Flextouch U-100 | 67 | $52,493 | $783 |
| Ozempic | 32 | $51,076 | $1,596 |
| Humalog Kwikpen U-100 | 49 | $47,586 | $971 |
| Tradjenta | 46 | $46,419 | $1,009 |
| Forteo | 12 | $43,344 | $3,612 |
| Victoza 2-Pak | 56 | $41,304 | $738 |
| Humalog Kwikpen U-200 | 22 | $38,687 | $1,758 |
| Lantus Solostar | 66 | $34,543 | $523 |
| Januvia | 27 | $32,928 | $1,220 |
| Toujeo Solostar | 43 | $32,002 | $744 |
| Humalog Mix 75-25 Kwikpen | 12 | $25,447 | $2,121 |
| Lantus | 51 | $24,193 | $474 |
| Testosterone | 26 | $22,204 | $854 |
| Novolog | 28 | $19,314 | $690 |
| Levemir Flextouch | 21 | $18,931 | $901 |
| Janumet Xr | 24 | $17,532 | $731 |
| Humalog | 19 | $17,328 | $912 |
| Ultra-Fine Nano Pen Needle | 151 | $14,439 | $96 |
| Bydureon Bcise | 13 | $14,130 | $1,087 |
| Basaglar Kwikpen U-100 | 33 | $13,613 | $413 |
| Synthroid | 80 | $7,076 | $88 |
| Levothyroxine | 198 | $5,000 | $25 |
| Rosuvastatin | 77 | $4,285 | $56 |
| Novolin 70-30 | 23 | $3,852 | $167 |
| Metformin Hcl Er | 158 | $2,965 | $19 |
| Atorvastatin | 111 | $2,801 | $25 |
| Ultra-Fine Mini Pen Needle | 27 | $2,421 | $90 |
| Nano 2nd Gen Pen Needle | 30 | $2,412 | $80 |
| Repaglinide | 21 | $2,388 | $114 |
| Levoxyl | 40 | $2,310 | $58 |
| Novolin N | 18 | $2,057 | $114 |
| Pioglitazone | 67 | $1,996 | $30 |
| Metformin | 209 | $1,988 | $10 |
| Glipizide Er | 55 | $1,684 | $31 |
| Glipizide | 131 | $1,625 | $12 |
| Acarbose | 18 | $1,438 | $80 |
| Nateglinide | 13 | $1,406 | $108 |
| Alendronate | 106 | $1,239 | $12 |
| Hydrocortisone | 31 | $1,025 | $33 |
| Losartan | 67 | $983 | $15 |
| Novolin R | 26 | $970 | $37 |
| Testosterone Cypionate | 17 | $767 | $45 |
| Veo Insulin | 21 | $743 | $35 |
| Methimazole | 79 | $692 | $9 |
| Insulin | 19 | $622 | $33 |
| Lisinopril | 43 | $385 | $9 |
| Hydrochlorothiazide | 44 | $360 | $8 |
| Amlodipine Besylate | 44 | $341 | $8 |
| Gabapentin | 12 | $233 | $19 |
| Spironolactone | 12 | $214 | $18 |
| Amlodipine Besylate-Benazepril | 14 | $81 | $6 |
| Benazepril | 11 | $48 | $4 |
| Dexamethasone | 25 | $41 | $2 |
2019: 57 drugs
| Trulicity | 313 | $373,617 | $1,194 |
| Forteo | 29 | $99,272 | $3,423 |
| Novolog Flexpen | 78 | $96,252 | $1,234 |
| Victoza 3-Pak | 54 | $94,271 | $1,746 |
| Jardiance | 76 | $69,225 | $911 |
| Victoza 2-Pak | 67 | $58,589 | $874 |
| Novolog Mix 70-30 Flexpen | 44 | $52,973 | $1,204 |
| Humalog Kwikpen U-100 | 52 | $51,651 | $993 |
| Tresiba Flextouch U-100 | 64 | $44,996 | $703 |
| Lantus Solostar | 66 | $39,464 | $598 |
| Humalog Kwikpen U-200 | 17 | $38,991 | $2,294 |
| Toujeo Solostar | 47 | $36,265 | $772 |
| Tradjenta | 33 | $35,210 | $1,067 |
| Ozempic | 21 | $31,035 | $1,478 |
| Humalog | 37 | $30,524 | $825 |
| Januvia | 23 | $27,803 | $1,209 |
| Lantus | 53 | $24,033 | $453 |
| Levemir Flextouch | 28 | $20,557 | $734 |
| Bydureon Bcise | 14 | $18,745 | $1,339 |
| Testosterone | 19 | $17,994 | $947 |
| Novolog | 22 | $14,508 | $659 |
| Ultra-Fine Nano Pen Needle | 159 | $12,660 | $80 |
| Janumet Xr | 23 | $12,158 | $529 |
| Synthroid | 79 | $7,026 | $89 |
| Basaglar Kwikpen U-100 | 17 | $6,196 | $364 |
| Novolin 70-30 | 15 | $4,171 | $278 |
| Levothyroxine | 182 | $3,967 | $22 |
| Novolin N | 24 | $3,654 | $152 |
| Metformin Hcl Er | 174 | $3,367 | $19 |
| Rosuvastatin | 61 | $3,328 | $55 |
| Nateglinide | 13 | $2,896 | $223 |
| Atorvastatin | 98 | $2,406 | $25 |
| Metformin | 202 | $2,031 | $10 |
| Glipizide Er | 53 | $2,010 | $38 |
| Pioglitazone | 78 | $1,891 | $24 |
| Glipizide | 134 | $1,652 | $12 |
| Ultra-Fine Mini Pen Needle | 16 | $1,425 | $89 |
| Alendronate | 156 | $1,349 | $9 |
| Novolin R | 26 | $896 | $34 |
| Levoxyl | 22 | $889 | $40 |
| Liothyronine | 15 | $884 | $59 |
| Hydrocortisone | 29 | $827 | $29 |
| Repaglinide | 15 | $804 | $54 |
| Losartan | 50 | $741 | $15 |
| Droplet Pen Needle | 15 | $730 | $49 |
| Veo Insulin | 21 | $690 | $33 |
| Methimazole | 66 | $624 | $9 |
| Insulin | 20 | $597 | $30 |
| Testosterone Cypionate | 19 | $521 | $27 |
| Cyred Eq | 12 | $423 | $35 |
| Spironolactone | 18 | $390 | $22 |
| Amlodipine Besylate | 45 | $372 | $8 |
| Lisinopril | 49 | $363 | $7 |
| Hydrochlorothiazide | 40 | $332 | $8 |
| Amlodipine Besylate-Benazepril | 11 | $163 | $15 |
| Benazepril | 16 | $126 | $8 |
| Dexamethasone | 23 | $54 | $2 |
2018: 54 drugs
| Forteo | 34 | $134,074 | $3,943 |
| Trulicity | 104 | $132,455 | $1,274 |
| Novolog Flexpen | 77 | $77,163 | $1,002 |
| Humalog Kwikpen U-100 | 66 | $60,242 | $913 |
| Humalog Kwikpen U-200 | 31 | $55,601 | $1,794 |
| Novolog Mix 70-30 Flexpen | 37 | $49,890 | $1,348 |
| Toujeo Solostar | 70 | $48,665 | $695 |
| Lantus Solostar | 92 | $46,672 | $507 |
| Victoza 3-Pak | 28 | $46,484 | $1,660 |
| Jardiance | 60 | $41,223 | $687 |
| Tradjenta | 49 | $38,324 | $782 |
| Januvia | 32 | $36,199 | $1,131 |
| Bydureon Bcise | 48 | $33,589 | $700 |
| Victoza 2-Pak | 40 | $27,582 | $690 |
| Lantus | 56 | $23,904 | $427 |
| Janumet | 23 | $23,106 | $1,005 |
| Tresiba Flextouch U-100 | 48 | $22,435 | $467 |
| Humulin R U-500 Kwikpen | 25 | $21,233 | $849 |
| Levemir Flextouch | 36 | $16,487 | $458 |
| Novolog | 20 | $15,724 | $786 |
| Humalog | 20 | $14,114 | $706 |
| Ultra-Fine Nano Pen Needle | 153 | $12,190 | $80 |
| Janumet Xr | 20 | $8,991 | $450 |
| Humulin 70-30 | 19 | $6,198 | $326 |
| Humulin 70/30 Kwikpen | 12 | $6,182 | $515 |
| Synthroid | 107 | $5,728 | $54 |
| Basaglar Kwikpen U-100 | 13 | $4,237 | $326 |
| Levothyroxine | 174 | $3,383 | $19 |
| Rosuvastatin | 54 | $3,073 | $57 |
| Metformin Hcl Er | 164 | $2,961 | $18 |
| Glipizide Er | 73 | $2,810 | $38 |
| Atorvastatin | 121 | $2,354 | $19 |
| Novolin N | 14 | $2,221 | $159 |
| Ultra-Fine Mini Pen Needle | 27 | $1,803 | $67 |
| Metformin | 159 | $1,735 | $11 |
| Pioglitazone | 88 | $1,528 | $17 |
| Glipizide | 135 | $1,502 | $11 |
| Ezetimibe | 17 | $1,204 | $71 |
| Hydrocortisone | 25 | $899 | $36 |
| Alendronate | 93 | $838 | $9 |
| Repaglinide | 11 | $655 | $60 |
| Veo Insulin | 18 | $617 | $34 |
| Pravastatin | 12 | $559 | $47 |
| Methimazole | 57 | $523 | $9 |
| Testosterone Cypionate | 34 | $360 | $11 |
| Hydrochlorothiazide | 48 | $345 | $7 |
| Lisinopril | 40 | $334 | $8 |
| Losartan | 36 | $320 | $9 |
| Amlodipine Besylate | 50 | $253 | $5 |
| Insulin | 11 | $238 | $22 |
| Spironolactone | 17 | $231 | $14 |
| Metoprolol | 11 | $169 | $15 |
| Simvastatin | 12 | $70 | $6 |
| Dexamethasone | 18 | $30 | $2 |
2017: 54 drugs
| Forteo | 29 | $94,623 | $3,263 |
| Humalog Kwikpen U-100 | 94 | $90,324 | $961 |
| Humalog Kwikpen U-200 | 33 | $68,274 | $2,069 |
| Novolog Flexpen | 84 | $65,680 | $782 |
| Lantus Solostar | 114 | $52,608 | $461 |
| Toujeo Solostar | 85 | $50,071 | $589 |
| Novolog Mix 70-30 Flexpen | 36 | $45,766 | $1,271 |
| Januvia | 40 | $42,331 | $1,058 |
| Trulicity | 44 | $39,245 | $892 |
| Lantus | 64 | $28,829 | $450 |
| Levemir Flextouch | 44 | $25,090 | $570 |
| Victoza 3-Pak | 13 | $20,385 | $1,568 |
| Humulin R U-500 Kwikpen | 27 | $18,790 | $696 |
| Tradjenta | 31 | $16,932 | $546 |
| Novolog | 36 | $16,765 | $466 |
| Janumet | 17 | $13,521 | $795 |
| Humalog | 37 | $12,905 | $349 |
| Humalog Mix 75-25 Kwikpen | 18 | $12,632 | $702 |
| Invokana | 11 | $11,882 | $1,080 |
| Ultra-Fine Nano Pen Needle | 116 | $8,217 | $71 |
| Androgel | 11 | $8,083 | $735 |
| Synthroid | 84 | $4,304 | $51 |
| Bd Ultra-Fine Pen Needle | 35 | $4,097 | $117 |
| Janumet Xr | 11 | $3,907 | $355 |
| Atorvastatin | 139 | $2,764 | $20 |
| Levothyroxine | 117 | $2,529 | $22 |
| Novolin N | 24 | $2,187 | $91 |
| Metformin Hcl Er | 149 | $2,094 | $14 |
| Rosuvastatin | 23 | $1,927 | $84 |
| Glipizide Er | 57 | $1,901 | $33 |
| Metformin | 151 | $1,598 | $11 |
| Glipizide | 162 | $1,341 | $8 |
| Ultra-Fine Mini Pen Needle | 18 | $1,175 | $65 |
| Insulin | 34 | $975 | $29 |
| Pioglitazone | 51 | $909 | $18 |
| Novolin 70-30 | 12 | $897 | $75 |
| Hydrocortisone | 21 | $825 | $39 |
| Insulin | 20 | $787 | $39 |
| Alendronate | 96 | $767 | $8 |
| Insulin | 18 | $669 | $37 |
| Glimepiride | 23 | $512 | $22 |
| Methimazole | 50 | $396 | $8 |
| Pravastatin | 13 | $391 | $30 |
| Lisinopril | 54 | $371 | $7 |
| Levoxyl | 13 | $343 | $26 |
| Hydrochlorothiazide | 38 | $327 | $9 |
| Glipizide Xl | 16 | $300 | $19 |
| Valsartan | 14 | $268 | $19 |
| Amlodipine Besylate | 41 | $201 | $5 |
| Losartan | 21 | $171 | $8 |
| Spironolactone | 20 | $169 | $8 |
| Simvastatin | 18 | $112 | $6 |
| Fluvastatin Er | 12 | $60 | $5 |
| Dexamethasone | 22 | $45 | $2 |
2016: 52 drugs
| Novolog Flexpen | 81 | $77,096 | $952 |
| Humalog Kwikpen U-100 | 93 | $68,778 | $740 |
| Lantus Solostar | 112 | $53,470 | $477 |
| Januvia | 63 | $49,735 | $789 |
| Levemir Flextouch | 50 | $30,259 | $605 |
| Lantus | 50 | $26,450 | $529 |
| Novolog Mix 70-30 | 24 | $25,061 | $1,044 |
| Humalog Mix 75-25 Kwikpen | 34 | $20,720 | $609 |
| Sensipar | 13 | $18,465 | $1,420 |
| Novolog Mix 70-30 Flexpen | 22 | $15,875 | $722 |
| Humalog | 25 | $15,663 | $627 |
| Humulin 70/30 Kwikpen | 13 | $10,040 | $772 |
| Bd Ultra-Fine Pen Needle | 170 | $9,998 | $59 |
| Tradjenta | 15 | $9,441 | $629 |
| Trulicity | 11 | $8,569 | $779 |
| Toujeo Solostar | 14 | $8,011 | $572 |
| Novolog | 21 | $7,625 | $363 |
| Crestor | 18 | $7,277 | $404 |
| Invokana | 11 | $6,258 | $569 |
| Victoza 2-Pak | 11 | $6,073 | $552 |
| Humulin N | 19 | $3,900 | $205 |
| Atorvastatin | 131 | $3,291 | $25 |
| Humulin R | 15 | $3,289 | $219 |
| Metformin Hcl Er | 106 | $3,117 | $29 |
| Synthroid | 49 | $2,983 | $61 |
| Valsartan | 21 | $2,803 | $133 |
| Fluvastatin | 18 | $2,540 | $141 |
| Levothyroxine | 68 | $1,652 | $24 |
| Metformin | 147 | $1,473 | $10 |
| Insulin | 38 | $1,288 | $34 |
| Glipizide | 156 | $1,282 | $8 |
| Pioglitazone | 51 | $796 | $16 |
| Insulin | 31 | $775 | $25 |
| Novolin N | 12 | $748 | $62 |
| Alendronate | 111 | $629 | $6 |
| Glipizide Er | 25 | $613 | $25 |
| Hydrocortisone | 21 | $612 | $29 |
| Pravastatin | 13 | $590 | $45 |
| Insulin | 16 | $569 | $36 |
| Lisinopril | 63 | $531 | $8 |
| Metoprolol | 14 | $460 | $33 |
| Glimepiride | 25 | $392 | $16 |
| Unifine Pentips | 12 | $380 | $32 |
| Methimazole | 31 | $345 | $11 |
| Glipizide Xl | 14 | $310 | $22 |
| Chlorthalidone | 12 | $295 | $25 |
| Amlodipine Besylate | 29 | $268 | $9 |
| Hydrochlorothiazide | 23 | $251 | $11 |
| Simvastatin | 20 | $175 | $9 |
| Losartan | 11 | $89 | $8 |
| Clonidine | 12 | $83 | $7 |
| Dexamethasone | 20 | $63 | $3 |
2015: 37 drugs
| Novolog Flexpen | 78 | $54,432 | $698 |
| Januvia | 70 | $53,471 | $764 |
| Humalog Kwikpen U-100 | 62 | $48,705 | $786 |
| Lantus Solostar | 89 | $37,597 | $422 |
| Lantus | 54 | $28,108 | $521 |
| Levemir Flextouch | 37 | $21,057 | $569 |
| Victoza 3-Pak | 23 | $20,498 | $891 |
| Invokana | 16 | $15,435 | $965 |
| Novolog | 30 | $13,919 | $464 |
| Humalog | 22 | $8,997 | $409 |
| Crestor | 26 | $8,055 | $310 |
| Bd Ultra-Fine Pen Needle | 141 | $6,655 | $47 |
| Novolog Mix 70-30 | 13 | $6,049 | $465 |
| Humulin 70/30 Kwikpen | 13 | $5,485 | $422 |
| Onglyza | 11 | $4,178 | $380 |
| Repaglinide | 21 | $2,940 | $140 |
| Synthroid | 47 | $2,487 | $53 |
| Atorvastatin | 89 | $2,425 | $27 |
| Metformin Hcl Er | 38 | $1,908 | $50 |
| Metformin | 86 | $1,157 | $13 |
| Levothyroxine | 42 | $955 | $23 |
| Pioglitazone | 30 | $933 | $31 |
| Glipizide | 119 | $866 | $7 |
| Glimepiride | 42 | $779 | $19 |
| Insulin | 22 | $727 | $33 |
| Hydrocortisone | 22 | $453 | $21 |
| Insulin | 13 | $415 | $32 |
| Methimazole | 42 | $411 | $10 |
| Amlodipine Besylate | 22 | $309 | $14 |
| Alendronate | 43 | $296 | $7 |
| Simvastatin | 26 | $284 | $11 |
| Chlorthalidone | 12 | $252 | $21 |
| Hydrochlorothiazide | 30 | $239 | $8 |
| Insulin | 12 | $237 | $20 |
| Gabapentin | 13 | $137 | $11 |
| Lisinopril | 13 | $94 | $7 |
| Carvedilol | 11 | $48 | $4 |
2014: 28 drugs
| Novolog Flexpen | 75 | $32,047 | $427 |
| Januvia | 42 | $31,343 | $746 |
| Humalog | 65 | $31,146 | $479 |
| Lantus Solostar | 71 | $24,469 | $345 |
| Victoza 3-Pak | 31 | $19,456 | $628 |
| Lantus | 31 | $11,247 | $363 |
| Levemir Flexpen | 26 | $8,616 | $331 |
| Bd Ultra-Fine Pen Needle | 135 | $7,058 | $52 |
| Repaglinide | 31 | $6,646 | $214 |
| Humalog Mix 75-25 | 15 | $5,429 | $362 |
| Novolog | 15 | $4,632 | $309 |
| Metformin Hcl Er | 26 | $4,382 | $169 |
| Levemir | 19 | $4,321 | $227 |
| Onglyza | 12 | $3,459 | $288 |
| Synthroid | 42 | $1,460 | $35 |
| Metformin | 56 | $850 | $15 |
| Atorvastatin | 29 | $797 | $27 |
| Glimepiride | 43 | $542 | $13 |
| Levothyroxine | 26 | $531 | $20 |
| Insulin | 16 | $491 | $31 |
| Insulin | 16 | $475 | $30 |
| Methimazole | 40 | $449 | $11 |
| Glipizide | 44 | $383 | $9 |
| Alendronate | 43 | $341 | $8 |
| Simvastatin | 20 | $234 | $12 |
| Losartan | 11 | $178 | $16 |
| Hydrochlorothiazide | 18 | $122 | $7 |
| Amlodipine Besylate | 11 | $92 | $8 |
2013: 31 drugs
| Novolog Flexpen | 98 | $39,686 | $405 |
| Januvia | 116 | $31,899 | $275 |
| Lantus Solostar | 109 | $27,691 | $254 |
| Prandin | 32 | $11,388 | $356 |
| Humalog | 31 | $10,152 | $327 |
| Bd Ultra-Fine Pen Needle | 137 | $6,572 | $48 |
| Byetta | 14 | $4,730 | $338 |
| Crestor | 21 | $4,642 | $221 |
| Glumetza | 16 | $4,158 | $260 |
| Lantus | 16 | $3,314 | $207 |
| Levemir Flexpen | 12 | $3,239 | $270 |
| Nateglinide | 19 | $1,697 | $89 |
| Pioglitazone | 17 | $1,390 | $82 |
| Metformin | 74 | $953 | $13 |
| Hydrocortisone | 28 | $834 | $30 |
| Methimazole | 50 | $814 | $16 |
| Alendronate | 77 | $757 | $10 |
| Synthroid | 16 | $621 | $39 |
| Levothyroxine | 70 | $616 | $9 |
| Glimepiride | 58 | $583 | $10 |
| Atorvastatin | 20 | $534 | $27 |
| Sure Comfort | 16 | $507 | $32 |
| Glyburide | 16 | $455 | $28 |
| Simvastatin | 39 | $257 | $7 |
| Amlodipine Besylate | 20 | $223 | $11 |
| Losartan | 16 | $198 | $12 |
| Gabapentin | 13 | $170 | $13 |
| Hydrochlorothiazide | 11 | $153 | $14 |
| Lisinopril | 13 | $138 | $11 |
| Metoprolol | 14 | $87 | $6 |
| Atenolol | 14 | $82 | $6 |
Money from drug and device companies
$40 in 2025
| 2025 | 1 | 1 | None | $40 |
| 2024 | 1 | 1 | None | $164 |
| 2020 | 2 | 2 | None | $34 |
| 2019 | 3 | 4 | None | $163 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Dexcom | Dexcom G6 Transmitter | $40 | 1 payment
|
See the published payment
| Dexcom | Meals · 2025-12-19 | Dexcom G6 Transmitter | $40 |
See earlier years (2024, 2020, 2019)
2024: $164
| Beta Bionics | Ilet Bionic Pancreas | $164 | 1 payment
|
2020: $34
| Amgen | Evenity | $21 | 1 payment
|
| Mannkind | Afrezza | $14 | 1 payment
|
2019: $163
| Medtronic MiniMed | Minimed 670g System | $64 | 1 payment
|
| Mannkind | Afrezza | $59 | 1 payment
|
| Antares Pharma | Xyosted | $39 | 2 payments
|
Professional record
- NPI
- 1770791782
- Licence
- CA A116528, PA MD433677California A116528: Current · expires 2028-10-31
- Trained
- University of Missouri, Columbia School of Medicine, 2005 · 21 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- PA 1022479030001
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-05-21
- NPI last updated
- 2020-05-28
- NPI record certified
- 2020-05-28
This is when the NPI record was last certified, not a medical board exam.